Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Clin Exp Dermatol. 2022 Dec;47(12):2166-2175. doi: 10.1111/ced.15340. Epub 2022 Oct 27.
Patients with atopic dermatitis (AD) frequently use acupuncture (ACU) and osteopathic medicine (OM), although their therapeutic benefits are unclear.
To investigate the effectiveness of ACU and OM in patients with AD.
In a three-armed, single-centre, randomized controlled open explorative clinical trial, adult patients with AD received ACU, OM or no study intervention (control group; CG) plus routine care. Outcomes included disease severity (SCORing Atopic Dermatitis; SCORAD), itching intensity (visual analogue scale; VAS), frequency of topical corticosteroid (TCS) use over 7 days and cost-effectiveness. Endpoints were analysed by analysis of covariance adjusted for the respective baseline value and TCS use.
Overall, 121 patients (92 women, 29 men) with a mean ± SD age of 31.4 ± 10.5 years were randomized. After 12 weeks, the adjusted means (95% CI) for ACU, OM and control were, respectively, 22.3 (18.3-26.3), 26.4 (22.6-30.2) and 23.7 (19.9-27.5) for SCORAD (P = 0.32); 27.9 (19.5-36.4), 35.0 (26.9-43.0) and 42.3 (34.7-50.0) for VAS itching (P < 0.05); and 2.3 (0.8-3.9), 1.9 (0.4-3.5) and 4.3 (2.6-6.0), for TCS use (P = 0.10). ACU and OM were not cost-effective compared with the CG.
Although no differences in disease severity were found, our findings indicate that ACU might reduce itching in patients with AD. Furthermore, ACU and OM showed a trend towards reducing TCS use.
患有特应性皮炎（AD）的患者经常使用针灸（ACU）和整骨疗法（OM），尽管其治疗效果尚不清楚。
调查 ACU 和 OM 在 AD 患者中的疗效。
在一项三臂、单中心、随机对照开放性临床试验中，成年 AD 患者接受 ACU、OM 或无研究干预（对照组；CG）加常规护理。结果包括疾病严重程度（SCORing 特应性皮炎；SCORAD）、瘙痒强度（视觉模拟量表；VAS）、7 天内局部皮质类固醇（TCS）的使用频率和成本效益。终点通过协方差分析进行分析，调整了各自的基线值和 TCS 的使用。
共有 121 名（92 名女性，29 名男性）平均年龄（SD）为 31.4（10.5）岁的患者被随机分组。12 周后，ACU、OM 和 CG 的调整均值（95%CI）分别为 SCORAD 的 22.3（18.3-26.3）、26.4（22.6-30.2）和 23.7（19.9-27.5）（P=0.32）；VAS 瘙痒的 27.9（19.5-36.4）、35.0（26.9-43.0）和 42.3（34.7-50.0）（P<0.05）；TCS 使用的 2.3（0.8-3.9）、1.9（0.4-3.5）和 4.3（2.6-6.0）（P=0.10）。与 CG 相比，ACU 和 OM 没有成本效益。
尽管在疾病严重程度方面没有差异，但我们的发现表明 ACU 可能会减轻 AD 患者的瘙痒。此外，ACU 和 OM 显示出减少 TCS 使用的趋势。
